TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33062199

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33062236

Group type: EXPERIMENTAL
Intervention: Proprotein convertase subtilisin/kexin 9 inhibitor (PCSK9i) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Empagliflozin
Number of subjects: 0
Study: 33062284

Group type: EXPERIMENTAL
Intervention: Exergaming training using the Interactive Rehabilitation and Exercise System (IREX®)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Traditional gym-based exercise (TGB)
Number of subjects: 54
Study: 33062294

Group type: EXPERIMENTAL
Intervention: SafeCare+® (an evidence-based parenting curriculum augmented with a healthy relationships curriculum)
Number of subjects: 0

Group type: COMPARATOR
Intervention: SafeCare as usual (control group)
Number of subjects: 0
Study: 33062302

Group type: EXPERIMENTAL
Intervention: Pragmatic posterior capsular stretch (PPCS)
Number of subjects: 0
Study: 33062397

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography angiography (OCTA)
Number of subjects: 593

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 593
Study: 33062627

Group type: EXPERIMENTAL
Intervention: YH4808 (novel selective potassium-competitive acid blocker)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 33062629

Group type: EXPERIMENTAL
Intervention: Tofacitinib aspartate 7.13 mg (test formulation)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Tofacitinib citrate 8.08 mg (reference formulation)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both formulations (test and reference)
Number of subjects: 41
Study: 33062947

Group type: EXPERIMENTAL
Intervention: Nivolumab 40 mg every 2 weeks
Number of subjects: 30
Study: 33063141

Group type: EXPERIMENTAL
Intervention: Serological testing using venous blood and saliva samples collected in June/July 2020, October/November 2020, and March/April 2021.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bi-monthly questionnaires covering SARS-CoV-2 symptoms, health, preventive behavior, and lifestyle information.
Number of subjects: 0
Study: 33063185

Group type: EXPERIMENTAL
Intervention: 50 mg doxorubicin (DOX) and 10 mg mitomycin C emulsified 1:2 with ethiodized oil (Lipiodol) during conventional transarterial chemoembolization (cTACE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lipiodol distribution stratified (1 vs. ≥ 2 segments vs. lobar)
Number of subjects: 30
Study: 33063912

Group type: EXPERIMENTAL
Intervention: Religiously tailored and ethically balanced education
Number of subjects: 137
Study: 33064098

Group type: EXPERIMENTAL
Intervention: MRSA decolonization intervention (details not specified)
Number of subjects: 16
Study: 33064109

Group type: EXPERIMENTAL
Intervention: MEDiC kit (decolonization toolkit)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Workshop activities
Number of subjects: 16
Study: 33064186

Group type: EXPERIMENTAL
Intervention: Washed microbiota transplantation (WMT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 100
Study: 33064577

Group type: EXPERIMENTAL
Intervention: Rapid pharmacogenomic testing using the 2MoBiL (Mobile Molecular Biology Laboratory)
Number of subjects: 0
Study: 33064819

Group type: EXPERIMENTAL
Intervention: RBD BAT
Number of subjects: 263

Group type: COMPARATOR
Intervention: Baseline factor activity levels
Number of subjects: 263
Study: 33064988

Group type: EXPERIMENTAL
Intervention: Personalized neoantigen-based vaccine NEO-PV-01 plus PD-1 blockade
Number of subjects: 82
Study: 33066188

Group type: EXPERIMENTAL
Intervention: Telemedicine-based coagulation service (CS)
Number of subjects: 614

Group type: COMPARATOR
Intervention: Regular medical care (RMC)
Number of subjects: 614
Study: 33066724

Group type: EXPERIMENTAL
Intervention: Chronic migraine with medication overuse (CM-MO)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Detoxification protocol in CM-MO subjects
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Responders to detoxification in CM-MO (n=23)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Episodic migraine (EM)
Number of subjects: 55
Study: 33066794

Group type: EXPERIMENTAL
Intervention: One-month dual-antiplatelet therapy (DAPT) followed by 23-month ticagrelor monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12-month DAPT followed by 12-month aspirin alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 0
Study: 33066801

Group type: EXPERIMENTAL
Intervention: Viral load in lower respiratory tract (LRT) samples
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Viral shedding duration (time to negativity)
Number of subjects: 90
Study: 33067126

Group type: EXPERIMENTAL
Intervention: Antiangiogenic agents plus EGFR-TKIs
Number of subjects: 1295

Group type: COMPARATOR
Intervention: EGFR-TKIs alone
Number of subjects: 1295
Study: 33067260

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (rtCGM)
Number of subjects: 441
Study: 33067273

Group type: EXPERIMENTAL
Intervention: Neurology group
Number of subjects: 223

Group type: COMPARATOR
Intervention: MRI group
Number of subjects: 223
Study: 33067297

Group type: EXPERIMENTAL
Intervention: CC-1 bispecific PSMAxCD3 antibody administered after prophylactic interleukin-6 receptor blockade with tocilizumab (8 mg/kg body weight).
Number of subjects: 0
Study: 33067318

Group type: EXPERIMENTAL
Intervention: KTE-X19, an autologous anti-CD19 CAR T-cell therapy
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: rabbit antithymocyte globulin (ATG)
Number of subjects: 1
Study: 33067379

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ruxolitinib (JAK inhibitor)
Number of subjects: 0
Study: 33067382

Group type: EXPERIMENTAL
Intervention: Kidney transplantation
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 29
Study: 33067633

Group type: EXPERIMENTAL
Intervention: BAX 335 gene therapy (1 of 3 IV doses: 2.0 × 10^11; 1.0 × 10^12; or 3.0 × 10^12 vector genomes/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: BAX 335 gene therapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Corticosteroid treatment
Number of subjects: 8
Study: 33067775

Group type: EXPERIMENTAL
Intervention: Skeletal muscle index (SMI)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Skeletal muscle radiodensity (SMR)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Subcutaneous adipose tissue (SAT)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT)
Number of subjects: 646
Study: 33067999

Group type: EXPERIMENTAL
Intervention: Number of children parented (for females)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Motherhood (for females)
Number of subjects: 472

Group type: COMPARATOR
Intervention: Number of children parented (for males)
Number of subjects: 472
Study: 33068028

Group type: EXPERIMENTAL
Intervention: Peficitinib
Number of subjects: 989
Study: 33068284

Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg orally for 4 weeks followed by 2 weeks off)
Number of subjects: 10
Study: 33068794

Group type: EXPERIMENTAL
Intervention: Ramucirumab 10 mg/kg and Pembrolizumab 200 mg every 21 days for up to 35 cycles
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ramucirumab plus Pembrolizumab
Number of subjects: 26
Study: 33069228

Group type: EXPERIMENTAL
Intervention: PainAPP tool
Number of subjects: 38
Study: 33069648

Group type: EXPERIMENTAL
Intervention: Evolut R/PRO transcatheter aortic valves (TAVs)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Evolut R/PRO TAVs
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: TAV-sinus of Valsalva relation
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Mean TAV implantation depth
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Combination of factors (Evolut TAV, TAV-sinus of Valsalva relation, implantation depth)
Number of subjects: 300
Study: 33069650

Group type: EXPERIMENTAL
Intervention: Automated algorithm analyzing pre-PCI FFR pullback curve
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Major FFR gradient group
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Mixed FFR gradient group
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Minor FFR gradient group
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Absence of major FFR gradient lesion
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Presence of minor FFR gradient lesion
Number of subjects: 516
Study: 33069849

Group type: EXPERIMENTAL
Intervention: Intravascular lithotripsy (IVL)
Number of subjects: 431
Study: 33070058

Group type: EXPERIMENTAL
Intervention: Community-tailored dashboards (CTH intervention)
Number of subjects: 67
Study: 33070260

Group type: EXPERIMENTAL
Intervention: sintilimab (200 mg) plus chemotherapy (pemetrexed 500 mg/m2)
Number of subjects: 0
Study: 33070307

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 63
Study: 33070624

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Number of subjects: 108
Study: 33070964

Group type: EXPERIMENTAL
Intervention: Dysglycemia (prediabetes and diabetes)
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Highest quintile of fasting glucose (≥5.1 mmol/L)
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Highest 2-hour postload glucose quintile (≥6.9 mmol/L)
Number of subjects: 766

Group type: COMPARATOR
Intervention: Normoglycemia
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Glycated hemoglobin
Number of subjects: 766
Study: 33071007

Group type: EXPERIMENTAL
Intervention: Enhanced infection control procedures
Number of subjects: 2195

Group type: EXPERIMENTAL
Intervention: Personal protective equipment usage
Number of subjects: 2195

Group type: EXPERIMENTAL
Intervention: COVID-19 prevalence
Number of subjects: 2195

Group type: EXPERIMENTAL
Intervention: Symptoms of depression
Number of subjects: 2195

Group type: EXPERIMENTAL
Intervention: Symptoms of anxiety
Number of subjects: 2195

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 testing positivity rates
Number of subjects: 2195
Study: 33071013

Group type: EXPERIMENTAL
Intervention: Urinary 3-hydroxyisovaleryl carnitine (3-HIC) excretion
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Plasma biotin
Number of subjects: 694
Study: 33071107

Group type: EXPERIMENTAL
Intervention: Pre-pembrolizumab PET/CT
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Post-pembrolizumab PET/CT
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Baseline FDG-uptake
Number of subjects: 108
Study: 33071206

Group type: EXPERIMENTAL
Intervention: Home-based blood pressure monitoring
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Home-based LDL testing
Number of subjects: 45
Study: 33071968

Group type: EXPERIMENTAL
Intervention: hCG Triggering
Number of subjects: 8000
Study: 33072090

Group type: EXPERIMENTAL
Intervention: Gal3 knockout (Gal3KO) mice
Number of subjects: 2

Group type: COMPARATOR
Intervention: Polymyxin B (bactericidal antibiotic)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Clodronate (macrophage modulator)
Number of subjects: 2
Study: 33072126

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 1
Study: 33072397

Group type: EXPERIMENTAL
Intervention: Blocked practice of robot-assisted upper limb reaching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random practice of robot-assisted upper limb reaching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control week assessments (robot-assisted reaching tasks, Melbourne assessment 2, subscale fluency)
Number of subjects: 0
Study: 33072399

Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor T-cell therapy (CAR-T cell therapy)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Patient engagement in clinical trial protocol development
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Early economic analysis
Number of subjects: 2
Study: 33072620

Group type: EXPERIMENTAL
Intervention: L-thyroxine treatment
Number of subjects: 0
Study: 33072799

Group type: EXPERIMENTAL
Intervention: Cooked Broccoli
Number of subjects: 0
Study: 33072814

Group type: EXPERIMENTAL
Intervention: Prolonged low-dose methylprednisolone (MP)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control (no methylprednisolone)
Number of subjects: 173
Study: 33072885

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 169

Group type: COMPARATOR
Intervention: Vitamin K antagonists
Number of subjects: 169
Study: 33073219

Group type: EXPERIMENTAL
Intervention: rBCG-N-RSV vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 33073527

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus original chemotherapy regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Original chemotherapy regimen
Number of subjects: 0
Study: 33073557

Group type: EXPERIMENTAL
Intervention: COVID-19 biobank established with 46,677 samples collected from participants.
Number of subjects: 913
Study: 33073614

Group type: EXPERIMENTAL
Intervention: S-ICD implant
Number of subjects: 1111
Study: 33073631

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) for one hour
Number of subjects: 54
Study: 33074097

Group type: EXPERIMENTAL
Intervention: Traditional diet in Mer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Access to takeaway food and alcohol in Waiben
Number of subjects: 0
Study: 33074164

Group type: EXPERIMENTAL
Intervention: Advertisements on social media websites (Facebook, Instagram, Twitter)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Advertisements on dating apps (Grindr, Jack'd, Hornet)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Advertisements on informational websites (Google, Yahoo, Bing)
Number of subjects: 400
Study: 33074330

Group type: EXPERIMENTAL
Intervention: Infected children (H3N2)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Inactivated influenza vaccination (IIV)
Number of subjects: 44
Study: 33074373

Group type: EXPERIMENTAL
Intervention: Intravitreal injection or vitreoretinal surgery with incision distance of 3.5-4.0 mm posterior to the limbus.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Recommended incision distance of 4.0 mm for AL > 25 mm.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Recommended incision distance of 3.5 mm for AL < 22.5 mm.
Number of subjects: 200
Study: 33074401

Group type: EXPERIMENTAL
Intervention: Osilodrostat 10 mg twice daily
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Surgical resection of an atypical tumor
Number of subjects: 1
Study: 33074406

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with pressure control/assist mode
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Datasets with ineffective triggering
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined use of opioids and sedatives
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Severe ineffective triggering
Number of subjects: 100
Study: 33074470

Group type: EXPERIMENTAL
Intervention: Alcoholic Hepatitis (AH)
Number of subjects: 131
Study: 33074566

Group type: EXPERIMENTAL
Intervention: Radiomics signature rGEV based on noncontrast-enhanced CT images
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Radiomics signature rHRV based on noncontrast-enhanced CT images
Number of subjects: 161
Study: 33074703

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33074941

Group type: EXPERIMENTAL
Intervention: Maintenance fluids, nutritional fluids, drug fluids
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Diuretics or renal replacement therapy
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Sodium administration
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Potassium administration
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Fluid loss
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Mortality at 90 days
Number of subjects: 241
Study: 33075061

Group type: EXPERIMENTAL
Intervention: Bio-Germanium
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 33075126

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) in ACS patients
Number of subjects: 5782

Group type: COMPARATOR
Intervention: Single antiplatelet therapy (SAPT) in ACS patients
Number of subjects: 5782

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) in SIHD patients
Number of subjects: 5782

Group type: COMPARATOR
Intervention: Single antiplatelet therapy (SAPT) in SIHD patients
Number of subjects: 5782
Study: 33075140

Group type: EXPERIMENTAL
Intervention: Monitoring and adapting recruitment methods
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Flexible research team
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Provision of transportation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Regular information about the progress of the study
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low staff turnover
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Flexibility in appointment making
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Expression of appreciation by staff (letters, gifts, cards)
Number of subjects: 50
Study: 33075149

Group type: EXPERIMENTAL
Intervention: Docetaxel (original dose)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Docetaxel (individualised dose)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Neutrophil counts (first cycle)
Number of subjects: 366
Study: 33075159

Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Oral repaglinide
Number of subjects: 61

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 61

Group type: COMPARATOR
Intervention: Long-acting insulin glargine
Number of subjects: 61
Study: 33075344

Group type: EXPERIMENTAL
Intervention: IL-6 levels in compensated ACLD (cACLD) patients
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: IL-6 levels in decompensated ACLD (dACLD) patients
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: MELD score across all stages of ACLD
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: HVPG measurement in compensated ACLD patients
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: CRP levels across decompensated ACLD stages
Number of subjects: 168
Study: 33076864

Group type: EXPERIMENTAL
Intervention: Ziv-aflibercept intravitreal injection
Number of subjects: 20
Study: 33076939

Group type: EXPERIMENTAL
Intervention: rhEPO (500 U/kg, administered intravenously within 72 hours of birth and then once every other day for 2 weeks)
Number of subjects: 1898

Group type: EXPERIMENTAL
Intervention: rhEPO (500 U/kg)
Number of subjects: 1898

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 1898
Study: 33076994

Group type: EXPERIMENTAL
Intervention: Participants with ASD
Number of subjects: 162

Group type: COMPARATOR
Intervention: TD participants
Number of subjects: 162
Study: 33077004

Group type: EXPERIMENTAL
Intervention: Targeted gown and glove use during high-risk care activities
Number of subjects: 322
Study: 33077273

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist (VKA) treatment
Number of subjects: 294
Study: 33077562

Group type: EXPERIMENTAL
Intervention: 3D power Doppler (3DPD) angiography
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: Uterine artery Doppler acquisition
Number of subjects: 2200
Study: 33077658

Group type: EXPERIMENTAL
Intervention: Aztreonam 2 grams
Number of subjects: 0
Study: 33077867

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (IC)
Number of subjects: 3637

Group type: EXPERIMENTAL
Intervention: Non-intensive treatment
Number of subjects: 3637

Group type: EXPERIMENTAL
Intervention: Clinical trial (CT)
Number of subjects: 3637

Group type: EXPERIMENTAL
Intervention: Supportive care only (SC)
Number of subjects: 3637

Group type: COMPARATOR
Intervention: Intensive chemotherapy (IC) in 2007-2013 vs 1999-2006
Number of subjects: 3637

Group type: COMPARATOR
Intervention: Supportive care only (SC) in 2007-2013 vs 1999-2006
Number of subjects: 3637
Study: 33078076

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (MV)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Competing risks analysis considering death as a competing event
Number of subjects: 391
Study: 33078240

Group type: EXPERIMENTAL
Intervention: Mechanical power estimations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33078373

Group type: EXPERIMENTAL
Intervention: Formalin fixation of tumor specimens after infusion of panitumumab-IRDye800CW (25 or 50 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Formalin-fixed specimens
Number of subjects: 30
Study: 33078867

Group type: COMPARATOR
Intervention: Alirocumab
Number of subjects: 60997

Group type: COMPARATOR
Intervention: Evolocumab
Number of subjects: 60997
Study: 33078998

Group type: EXPERIMENTAL
Intervention: Whole-body MRI
Number of subjects: 45

Group type: COMPARATOR
Intervention: CT
Number of subjects: 45

Group type: COMPARATOR
Intervention: Bone scintigraphy
Number of subjects: 45
Study: 33079066

Group type: EXPERIMENTAL
Intervention: FMS program (intervention) involving peer modeling, parent engagement, and structured skills-based activities
Number of subjects: 72

Group type: COMPARATOR
Intervention: Unstructured physical activity (comparator) curriculum providing suggestions for child-led physical activity (free play)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: FMS program (intervention)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Unstructured physical activity (comparator) curriculum
Number of subjects: 72
Study: 33079068

Group type: EXPERIMENTAL
Intervention: Question Prompt List (QPL) yes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Motivation Enhancement System (MES) yes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Text message reminders yes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Question Prompt List (QPL) no
Number of subjects: 20

Group type: COMPARATOR
Intervention: Motivation Enhancement System (MES) no
Number of subjects: 20

Group type: COMPARATOR
Intervention: Text message reminders no
Number of subjects: 20
Study: 33079071

Group type: EXPERIMENTAL
Intervention: Nod smartphone app (experimental group, n=100)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control group (access after 4 weeks, n=121)
Number of subjects: 221